Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disea...
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but it may be associated with side effects and loss of response. One loss of response mechanism is increased IFX clearance (IFX-CL), resulting in short half-life and decreased troughs.MethodsPatients were recruited, and relevant demographic, clinical, and laboratory d...
Alternative Titles
Full title
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1680457063
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1680457063
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1097/MIB.0000000000000212
